Tempus Priority Study: A Pan-tumor Observational Study


Report Abuse


Observational study that will be collecting clinical and molecular health information from cancer patients who have received comprehensive genomic profiling and meet the specific eligibility criteria outlined for each cohort with the goal of conducting research to advance cancer care and create a dataset that furthers cancer research.

Study Overview

Start Date
October 19, 2020
Completion Date
October 19, 2030
Date Posted
January 5, 2022
Accepts Healthy Volunteers?


Full Address
UT Southwestern
Dallas, Texas 75390, United States

Baylor College of Medicine
Houston, Texas 77030, United States


Study Population
This protocol targets a broad spectrum of cancer patients with comprehensive genomic profiling.
Eligibility Criteria
Inclusion Criteria:

Solid or hematologic malignancy.
Willing and able to provide informed consent where required.
Has received or will receive genomic profiling.

Exclusion Criteria:

Individuals without the capacity to consent.
Prisoners at the time of enrollment.

I/E criteria are specific for each cohort of Group 2 and available in the full protocol.

Study Contact Info

Study Contact Name
Study Contact Email
Study Contact Phone

Contact Listings Owner Form

Tempus Priority Study: A Pan-tumor Observational Study 0 reviews

Write Your Review

There are no reviews yet.

Write Your Review

Your email address will not be published. Required fields are marked *

Other Details

FDA Regulated Drug?
FDA Regulated Device?
Detailed Description
The Study will collect combined clinical and molecular health information for cancer patients in the United States from multiple academic medical centers and community oncology practices. Participants who agree to join the Study will have their molecular profiling results, associated clinical health information, and longitudinal outcomes health information collected by the participating Institution for submission to Tempus. The specific goal of the Study is to create an outcomes-based dataset for future research to improve cancer treatment.
NCTid (if applicable)